30-Second Takeaway
- Instrumental-variable analysis of Medicare CABG suggests **no durable survival benefit** of multiarterial grafting versus single arterial grafting.
- Perioperative taxane-triplet plus checkpoint inhibitor ranked best for DFS in resectable G/GEJ adenocarcinoma but evidence is indirect.
- Phase 2 monotherapy oncology trials generally show worse efficacy and similar or higher toxicity than phase 3 evidence.
Week ending May 16, 2026
Five recent studies with implications for cardiac surgeons: MAG survival, perioperative systemic therapy rankings in G/GEJ cancer, neoadjuvant chemoimmunotherapy trial in resectable NSCLC, interpretation of the Win Ratio
Instrumental-variable analysis finds no survival advantage for multiarterial grafting in Medicare CABG patients
In 1,291,314 Medicare CABG recipients, conventional risk-adjusted models suggested MAG improved median survival by 0.41 years versus SAG. Using surgeon MAG rate as an instrumental variable eliminated that benefit, with identical standardized median survival of 10.38 years for MAG and SAG. The IV approach suggests prior observational MAG survival benefits reflect unmeasured confounding rather than treatment effect. Applicability is strongest to older Medicare beneficiaries; results do not address graft patency, quality-of-life, or younger populations.
Network meta-analysis ranks perioperative taxane-triplet plus ICI highest for DFS in resectable G/GEJ adenocarcinoma
Across 30 randomized trials (11,547 patients), perioperative P-Trp-Tax + ICI had the highest SUCRA for OS and DFS. The DFS benefit versus P-Trp-Tax alone was statistically supported (HR 0.72; 95% CrI 0.56–0.93), while OS effect was imprecise (HR 0.79; 95% CrI 0.59–1.05). No clear increase in high-grade adverse events with ICIs was observed, though toxicity estimates were heterogeneous. Findings rely heavily on indirect comparisons and limited direct head-to-head data, so results are hypothesis-generating rather than definitive guidance.
Phase III randomized trial launched comparing neoadjuvant chemoimmunotherapy versus upfront surgery in resectable stage II–III NSCLC
JCOG2317 randomizes 330 patients 1:1 to upfront surgery with adjuvant therapy versus neoadjuvant nivolumab plus platinum chemotherapy followed by surgery. Primary endpoint is overall survival; key secondary endpoints include PFS, time to distant metastasis, and objective response to neoadjuvant therapy. The trial tests whether perioperative chemoimmunotherapy improves long-term outcomes compared with current upfront-surgery standards. Results will directly inform perioperative strategy selection for resectable clinical stage II–III NSCLC when mature.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.